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A B S T R A C T
Background: The CHA2DS2VASc score has been used to evaluate the risk of thromboembolic events in
atrial ﬁbrillation. However, because all the components of CHA2DS2VASc are important cardiovascular
risk factors, we decided to evaluate the effectiveness of CHA2DS2VASc score as a long-term predictor for
prognosis in acute myocardial infarction (AMI) patients.
Methods: We enrolled 15,681 AMI patients for the Korean Working Group in Acute Myocardial Infarction
(KORMI) consecutively and analyzed retrospectively. We divided the all the patients into four groups
according to CHADS2VASc score (Group I: 0–1, n = 3317; Group II: 2–3, n = 6794; Group III: 4–5,
n = 4457; Group IV: 6–9, n = 1113). The cardiac event was deﬁned as the sum of all-cause mortality and
recurrence of myocardial infarction.
Results: As the risk score increased, the incidence of cardiac events was higher at 1, 6, 12, and 24 months.
The cardiac event-free survival rate was lower as the risk score increased (Group I vs Group II, p < 0.001;
Group II vs Group III, p < 0.001; Group III vs Group IV, p = 0.037). After adjusting confounding variables,
the Cox-regression multivariate analysis showed that the CHA2DS2VASc score was an independent
predictor for the long-term prognosis in total AMI patients (p < 0.001, hazard ratio = 1.414 per scale).
Conclusion: The AMI patients with higher CHA2DS2VASc score had worse cardiovascular outcome.
Therefore, CHADS2VASc score can be used to stratify AMI patients according to long-term prognosis
irrespective of presence of atrial ﬁbrillation.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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As the incidence of acute myocardial infarction (AMI)
increased and the survival rate from acute coronary events
improved, the risk-stratiﬁcation system for long-term prognosis
after acute myocardial infarction became important. There are
several risk-stratiﬁcation systems that were developed in
different study populations and included different contributing
factors.* Corresponding author at: Division of Cardiology, Department of Internal
Medicine, Gwangju Veterans Hospital, Sanwoldong 887-1, Gwangsangu, Gwangju
506-705, Republic of Korea. Tel.: +82 62 602 6100; fax: +82 62 602 6931.
E-mail address: omoegao@hanmail.net (S.H. Hwang).
http://dx.doi.org/10.1016/j.jjcc.2014.04.011
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsThe thrombolysis in myocardial infarction (TIMI) risk score,
based on results from ST-segment elevation myocardial infarction
(STEMI) patients eligible for thrombolytic therapy, suggested that
30-day mortality had a positive relationship with the risk score [1].
The Global Registry of Acute Coronary Events (GRACE) risk score
including eight contributing factors predicted in-hospital and 6-
month mortality independently among all the patients with an
acute coronary syndrome [2,3]. A recent study reported that
CHADS2 score, which was developed as a well-validated tool for
predicting risk of stroke in atrial ﬁbrillation patients, has strong
association with an all-cause mortality at 10 years in acute
coronary syndrome patients [4].
The CHA2DS2VASc score, a reﬁnement form of CHADS2 score,
was developed as a risk-stratiﬁcation tool for thromboembolic
events in patients with non-valvular atrial ﬁbrillation [5]. reserved.
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value of CHA2DS2VASc score in AMI. Therefore, we evaluated the
effectiveness of CHA2DS2VASc score as a risk-stratiﬁcation tool for
long-term clinical outcome in AMI patients.
Methods
Study population
This study enrolled 15,681 patients diagnosed as having AMI
consecutively from August 2008 to December 2011 and analyzed
the data retrospectively. These data are derived from the Korean
Working Group in Acute Myocardial Infarction (KORMI) registry,
which is a multi-centered and ongoing observational study
designed to collect and evaluate demographic, clinical, treatment,
and outcome data of patients with ACI. Because the KORMI is an
anonymous observational study, no informed consent of the
participating patients is required for the institutional boards at any
of the participating institutions.
Among the total enrolled patients, 8970 were diagnosed as
having ST-segment elevation myocardial infarction (STEMI) and
6711 patients were diagnosed as having non-ST-segment elevation
myocardial infarction (NSTEMI). The diagnostic criteria for AMI
were deﬁned as typical rise and fall of cardiac biomarker values
and at least one of the following: (1) symptoms of ischemia; (2)
development of pathologic Q wave in the electrocardiogram; (3)
new signiﬁcant ST segment or T wave change or new-onset left
bundle branch block; (4) identiﬁcation of intracoronary lesion by
angiography [6].
Unlike TIMI risk score or GRACE risk model which were
developed using populations treated by thrombolysis, our study
included all the patients with AMI irrespective of the method ofTable 1
Comparison of baseline characteristics among the four groups according to CHA2DS2
CHA2DS2VASc 4–5, Group IV: CHA2DS2VASc 6–9).
Low-risk Moderate-ris
Group I Group II 
n = 3317 n = 6794 
Age 50.5  8.2 61.5  11.3
Sex (male%) 3317 (100%) 5689 (83.7%)
SBP 127.2  26.6 128.5  29.2
DBP 80.5  29.4 79.2  26.7
LVEF 53.8  10.8 52.9  11.9
Max CK-MB 140  278 123  229 
Max troponin-I 42  95 41  93 
Total cholesterol (mg/dL) 193  42 180  45 
Triglyceride (mg/dL) 147  111 133  108 
HDL cholesterol (mg/dL) 43  13 43  15 
LDL cholesterol (mg/dL) 124  37 114  41 
Creatinine (mg/dL) 1.0  1.4 1.1  2.0 
Hs CRP 4.2  15.9 5.4  19.9
NT pro-BNP 637  1800 1755  4619 
Glycated hemoglobin (%) 6.1  2.6 6.6  2.0 
Previous IHD 290 (8.8%) 1020 (15.1%)
Hypertension 0 (0.0%) 3584 (52.2%)
Diabetes mellitus 0 (0.0%) 1728 (25.4%)
Dyslipidemia 351 (11.0%) 920 (14.2%) 
Old CVA 0 (0.0%) 54 (0.8%) 
Atrial ﬁbrillation 76 (2.3%) 223 (3.3%) 
Smoking 2805 (85.4%) 4454 (66.3%)
Aspirin 3240 (98.1%) 6641 (98.5%)
Clopidogrel 3175 (96.4%) 6500 (96.6%)
Beta blocker 2705 (83.6%) 5315 (80.6%)
ACE inhibitor 2129 (66.4%) 4213 (64.6%)
Angiotensin receptor blocker 623 (20.2%) 1537 (24.1%)
Statin 2593 (80.0%) 5113 (76.9%)
SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejecti
density lipoprotein; hs-CRP, high sensitivity C-reactive protein; NT pro-BNP, N-te
cerebrovascular accident; ACE inhibitor, angiotensin-converting enzyme inhibitor.treatment. Among STEMI patients, 8055 (89.8%) underwent
primary percutaneous coronary intervention (PCI), 323 patients
(3.6%) were treated for thrombolysis, and 592 patients (6.6%) were
treated by conservative treatment. Among NSTEMI patients, 4973
(74.1%) were treated by early invasive therapy and 1738 patients
were treated by early conservative strategy. We excluded the
patients diagnosed as having unstable angina or stable angina
pectoris.
The number of patients with atrial ﬁbrillation in AMI was 639
(3.9%) and this percentage is lower than the value suggested by
previous other studies [7].
Study protocol
We used CHA2DS2VASc score as a parameter to predict the long-
term outcome after AMI. CHA2DS2VASc score is a reﬁnement from
CHADS2 score which was developed to predict the possibility of
stroke and guide antithrombotic therapy. The components of
CHADS2 score are as follows: congestive heart failure, hyperten-
sion, age >75 years, diabetes mellitus, and history of stroke (2
points). CHA2DS2VASc score has several additional components:
age >65 years (1 point), age >75 years (2 points), history of
vascular disease, sex (female; 1 point). The history of myocardial
infarction was regarded as ‘‘vascular disease’’ and AMI was
counted as 1 point.
We divided all the enrolled patients into four groups according
to CHA2DS2VASc score: low-risk group (Group I: 0–1 point);
moderate-risk group (Group II: 2–3 points); high-risk group
(Group III: 4–5 points); and very high-risk group (Group IV: 6–9
points). We compared the in-hospital mortality and incidence of
cardiac event at 1, 6, 12, and 24 months and cumulative cardiac
event-free survival among the four groups irrespective of presenceVASc score (Group I: CHA2DS2VASc 0–1, Group II: CHA2DS2VASc 2–3, Group III:
k High-risk Very-high risk p-value
Group III Group IV
n = 4457 n = 1113
 73.8  9.3 77.6  7.5 <0.001
 1828 (41.0%) 288 (25.9%) <0.001
 127.8  31.0 129.3  32.7 0.092
 76.1  17.6 76.6  18.4 <0.001
 50.8  12.8 49.2  13.7 <0.001
99  209 78  145 <0.001
38  148 31  128 0.032
176  48 173  47 <0.001
115  84 114  66 <0.001
43  16 43  15 0.065
110  41 106  41 <0.001
1.3  2.2 1.4  1.4 <0.001
 7.9  25.1 10.8  32.5 <0.001
4689  8221 7586  10,309 <0.001
6.8  2.0 7.0  1.4 <0.001
 865 (19.5%) 260 (23.4%) <0.001
 3512 (78.8%) 1054 (94.7%) <0.001
 1870 (42.0%) 790 (71.0%) <0.001
526 (12.5%) 155 (15.1%) <0.001
453 (10.2%) 587 (52.7%) <0.001
251 (5.6%) 73 (6.6%) <0.001
 1472 (33.6%) 266 (24.3%) <0.001
 4315 (97.7%) 1068 (96.7%) <0.001
 4210 (95.7%) 1045 (94.6%) 0.002
 3377 (78.2%) 831 (76.7%) <0.001
 2579 (60.5%) 610 (57.2%) <0.001
 1185 (28.2%) 336 (31.4%) <0.001
 3124 (72.2%) 777 (71.5%) <0.001
on fraction; CK-MB, creatine kinase-MB; HDL, high-density lipoprotein; LDL, low-
rminal pro-brain type natriuretic peptide; IHD, ischemic heart disease; CVA,
Table 2
Comparison of in-hospital mortality and incidence of all-cause death and recurrence of myocardial infarction among the four groups divided by CHA2DS2VASc score (Group I:
CHA2DS2VASc 0–1, Group II: CHA2DS2VASc 2–3, Group III: CHA2DS2VASc 4–5, Group IV: CHA2DS2VASc 6–9).
Low-risk Moderate-risk High-risk Very-high risk p-value
Group I Group II Group III Group IV
n = 3317 n = 6794 n = 4457 n = 1113
In-hospital mortality 176/3312 (5.3) 364/6785 (5.4%) 220/4454 (4.9%) 55/1110 (5.0%) 0.751
Cardiac event at 1 month 24/2683 (0.9%) 72/5513 (1.3%) 68/3521 (1.9%) 19/841 (2.3%) 0.001
Cardiac event at 6 months 30/1707 (1.8%) 103/3614 (2.9%) 116/2336 (5.0%) 39/541 (7.2%) <0.001
Cardiac event at 12 months 36/1227 (2.9%) 128/2616 (4.9%) 155/1780 (8.7%) 48/419 (11.5%) <0.001
Cardiac event at 24 months 42/544 (6.9%) 147/1233 (11.9%) 175/933 (18.8%) 59/228 (25.9%) <0.001
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composite of recurrence of myocardial infarction and all-cause
mortality and we evaluated the predictive value of CHA2DS2VASc
score for long-term clinical outcome. Additionally, we performed
subgroup analysis and evaluated the prognostic role of CHA2DS2-
VASc score in STEMI and NSTEMI patients, respectively. Addition-
ally, the detailed cardiovascular outcomes such as cardiac death,
recurrence of myocardial infarction, non-cardiac death, and
repetition of PCI were compared among the four groups. The
mean follow-up duration was 9.4 months.
Statistical analysis
The baseline epidemiologic and clinical characteristics were
compared. The categorical baseline variables are presented as
counts and percentages and continuous variables are expressed as
average value  standard deviation. Differences of baseline character-
istics among the four groups according to CHA2DS2VASc score were
evaluated by student t-test for continuous variables and the Pearson
chi-square test for categorical variables. The in-hospital mortality and
incidence of cardiac events at 1, 6, 12, and 24 months are compared by
Pearson chi-square test. The cumulative cardiac event-free survivals
were compared among the four groups by Kaplan–Meier method in
total AMI patients and STEMI and NSTEMI patients respectively and
compared by log-rank method. In addition, to evaluate the predicative
value of CHA2DS2VASc score for long-term clinical outcome, we used
multivariate Cox-regression analysis. The co-variants for these
analyses were systolic blood pressure on presentation over 90 mmHg,
Killip class over II, left ventricular ejection fraction over 50%, pre-TIMI
ﬂow over I, and the use of beta-blocker, renin–angiotensin–aldosteroneFig. 1. Comparison of cumulative incidence of MACE according to CHA2DS2VASc risk gro
cardiac event; HR, hazard ratio; SBP, systolic blood pressure; TIMI, thrombolysis in myoc
aldosterone system.system (RAAS) blocker, and aspirin. Hazard ratios and 95% conﬁdence
intervals (CI) were calculated and all the tests were two-tailed: p-value
<0.05 was considered signiﬁcant. All the analyses were performed
using SPSS Version 18 (IBM, Chicago, IL, USA).
Results
Baseline characteristics
Several baseline characteristics which are components of
CHA2DS2VASc score were different necessarily among the four
groups. The patients in higher risk groups are older and the
percentage of females was higher as the risk score increased. The
prevalence of diabetes mellitus and hypertension and history of
cerebrovascular accident increased as the CHA2DS2VASc risk score
increased (Table 1).
Although the systolic blood pressure was not different among
the four groups, diastolic blood pressure was lower in higher risk
groups. As the risk score increased, left ventricular ejection fraction
was lower and the blood level of N-terminal pro-brain type
natriuretic peptide (NT pro-BNP) was higher. The laboratory values
such as cardiac enzymes, total cholesterol, low-density lipoprotein,
and triglyceride were different signiﬁcantly. As the CHA2DS2VASc
score increased, the level of creatinine, high-sensitivity C-reactive
protein (hs-CRP), and glycosylated hemoglobin (HbA1c) increased
(Table 1).
The prevalence of ischemic heart disease, dyslipidemia, and
atrial ﬁbrillation was higher in higher risk groups than in lower risk
groups and the frequency of use of medications was signiﬁcantly
different according to CHA2DS2VASc risk group. The percentage ofup (A) and Cox-regression multivariate analysis for MACE (B). MACE, major adverse
ardial infarction; LVEF, left ventricular ejection fraction; RAAS, renin–angiotensin–
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(Table 1).
Clinical outcome
Although the in-hospital mortality was not different among the
four groups (p = 0.751), the incidence of long-term cardiac events
increased as the CHA2DS2VASc risk score increased (p < 0.001)
(Table 2). Cardiac events were deﬁned as composite of all-cause
death and recurrence of myocardial infarction and evaluated at 1, 6,
12, and 24 months after AMI. The cumulative cardiac event-free
survival was higher in lower risk score groups than in higher risk
score groups (Group I vs Group II: p < 0.001, Group II vs Group III:
p < 0.001, Group III vs Group IV: p = 0.013) (Fig. 1A) and the
prognostic value of CHA2DS2VASc score for clinical outcome was
statistically signiﬁcant (hazard ratio per unit increase in the four-
grade risk groups = 1.384, p < 0.001) (Fig. 1B). In the Cox-regression
analysis, we adjusted several co-variants such as systolic bloodFig. 2. Comparison of detailed cardiac event according to CHA2DS2VASc risk group. Car
repetition of percutaneous coronary intervention (D).pressure, Killip class, left ventricular ejection fraction, chronic
kidney disease, and use of aspirin, beta-blocker, and angiotensin-
converting enzyme inhibitor. These variables are well-known
predictors of long-term clinical outcome after AMI. In our study,
presence of chronic kidney disease, systolic blood pressure, Killip
classiﬁcation over grade II, left ventricular ejection fraction over 50%,
and use of aspirin and RAAS blocker were independent predictors for
cumulative incidence of cardiac events during 2 years.
The detailed cardiovascular outcomes were analyzed by survival
analyses. The cumulative incidence of cardiac death increased as the
risk score increased (Group I vs Group II: p = 0.024, Group II vs Group
III: p = 0.003, Group III vs Group IV: p = 0.005) (Fig. 2A). However, the
recurrence rate of myocardial infarction and non-cardiac death rate
did not show deﬁnite positive correlation with CHA2DS2VASc (Fig. 2B
and C). The frequency of repetition of PCI which was excluded in the
primary end point showed a deﬁnite positive relationship with
CHA2DS2VASc (Group I vs Group II: p < 0.001, Group II vs Group III:
p < 0.001, Group III vs Group IV: p = 0.006) (Fig. 2D).diac death (A), recurrence of myocardial infarction (B), non-cardiac death (C), and
Fig. 3. Comparison of cumulative incidence of MACE according to CHA2DS2VASc risk group (A) and Cox-regression multivariate analysis for MACE (B) in STEMI patients.
MACE, major adverse cardiac event; STEMI, ST-segment elevation myocardial infarction; HR, hazard ratio; SBP, systolic blood pressure; TIMI, thrombolysis in myocardial
infarction; LVEF, left ventricular ejection fraction; RAAS, renin–angiotensin–aldosterone system.
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NSTEMI patients, respectively. The cumulative cardiac event-free
survival rate was lower as the risk score increased (Group I vs
Group II: p = 0.017, Group II vs Group III: p < 0.001, Group III vs
Group IV: p = 0.040) (Fig. 3A) and the predictive value of
CHA2DS2VASc score was statistically signiﬁcant (HR per unit
increase in the four-grade risk groups = 1.455, p = 0.001) (Fig. 3B).
Although the difference between Group III and Group IV was not
deﬁnite in NSTEMI patients, the difference in cardiac event-free
survival rate was similar in STEMI patients (Group I vs Group II:
p = 0.064, Group II vs Group III: p < 0.001, Group III vs Group IV:
p = 0.154) (Fig. 4A). The predictive value of CHA2DS2VASc score
was also statistically signiﬁcant in NSTEMI patients (HR per unit
increase in the four-grade risk groups = 1.298, p = 0.048) (Fig. 4B).
Discussion
From these results, we can conclude that CHA2DS2VASc score
on admission is an effective tool to predict long-term cardiovas-
cular outcome after AMI, and CHA2DS2VASc score can be used as aFig. 4. Comparison of cumulative incidence of MACE according to CHA2DS2VASc risk gr
MACE, major adverse cardiac event; NSTEMI, non-ST-segment elevation myocardial 
myocardial infarction; LVEF, left ventricular ejection fraction; RAAS, renin–angiotensinrisk-stratiﬁcation system in AMI irrespective of presence of atrial
ﬁbrillation and type of treatment strategy.
The CHA2DS2VASc score was developed to improve risk
stratiﬁcation in atrial ﬁbrillation patients with low CHADS2 score
(0–1) and the age of 65–74 years, female sex and vascular disease
are additional components to CHADS2 score. All the components of
CHA2DS2VASc are important risk and prognostic factors for
cardiovascular disease. Avezum et al. [8] suggested that hospital
mortality adjusted for confounding variables was higher in older
age groups. A study reported that hypertension, diabetes mellitus,
and congestive heart failure are long-term prognostic predictors
after AMI [9]. Malmberg et al. [10] reported that diabetes mellitus
was an independent predictor for all-cause mortality, as well as
cardiovascular death, recurrent myocardial infarction, stroke, and
congestive heart failure in unstable angina or non-Q-wave
myocardial infarction patients.
Although not signiﬁcant in multivariate analysis, a recent report
suggested that women had a higher primary composite of death
and heart failure than men after AMI [11]. Therefore, all the
components of CHA2DS2VASc score have a close association with
clinical outcome in AMI patients.oup (A) and Cox-regression multivariate analysis for MACE (B) in NSTEMI patients.
infarction; HR, hazard ratio; SBP, systolic blood pressure; TIMI, thrombolysis in
–aldosterone system.
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risk stratiﬁcation in AMI patients and recommended as a guideline
by multiple organizations, this risk score is difﬁcult to calculate
and needs a computerized system. In contrast to the complexity of
the GRACE risk model, the CHADS2 score is a comprehensive, fast,
and simple method in risk stratiﬁcation [4]. Because the
predictability of CHA2DS2VASc score is more powerful than
CHADS2 score, it is reasonable to use CHA2DS2VASc score to
predict the long-term clinical outcome of AMI more accurately and
easily.
Among baseline characteristics, the levels of NT pro-BNP and
hs-CRP have close linear relationships with CHA2DS2VASc risk
score. The elevated level of NT pro-BNP is known to be associated
with increased mortality and has predictive value in STEMI and
NSTEMI patients [12–17]. In particular, Khan et al. [18] suggested
that NT pro-BNP was better than TIMI risk score in predicting
mortality after AMI and Ang et al. [19] reported that BNP can
predict cardiovascular events over the GRACE risk score in acute
coronary syndrome patients. Additionally, some studies have
shown that the level of hs-CRP predicts the risk of in-hospital or
long-term mortality after myocardial infarction [20,21]. On the
basis of these ﬁndings, we can verify indirectly that CHA2DS2VASc
score is a powerful predictor for cardiovascular events in AMI
patients.
As the scale of risk group increased, the average hazard
ratio was 1.384 in total AMI patients. This hazard ratio was
signiﬁcant in STEMI patients (HR = 1.455, p < 0.001) and NSTEMI
patients (HR = 1.298, p = 0.048). The CHA2DS2VASc score is a
more important predictor in STEMI patients than in NSTEMI
patients.
Our study included all the AMI patients irrespective of
treatment method. TIMI risk score and GRACE risk score were
validated from studies that enrolled populations treated with
thrombolytic therapy. On the other hand, the Zwolle primary PCI
index and the CADILLAC risk score have been developed and
validated for STEMI patients undergoing primary PCI [22,23].
These risk models include the angiographic ﬁndings such as TIMI
ﬂow and presence of three-vessel disease. Contrary to risk models
described above, our study included all the STEMI patients and
NSTEMI patients irrespective of treatment strategy and showed a
close relationship between CHA2DS2VASc score and long-term
cardiovascular outcome.
There are several limitations to this study. Although
many patients were enrolled, it is a retrospective study. It is
necessary to perform a prospective cohort study to evaluate
the prognostic role of CHA2DS2VASc more accurately. The
second limitation of our study is that many baseline character-
istics are different among the four risk groups. Despite using
multivariate analysis to overcome this shortcoming, we are not
sure whether all the variables that can affect the clinical
outcome are adjusted completely. However, important variables,
which are known as contributors to cardiovascular outcome in
myocardial infarction such as blood pressure, chronic kidney
disease, Killip class, TIMI ﬂow, left ventricular ejection fraction,
and use of aspirin, beta-blocker and RAAS blocker, were adjusted
appropriately.
Despite these limitations, our study showed that CHA2DS2-
VASc score is an independent predictor for long-term
prognosis in AMI patients and can be used as a risk-stratiﬁcation
system. This ﬁnding was applicable to all the AMI patients
irrespective of type of AMI, type of treatment strategy,
and presence of atrial ﬁbrillation. Because CHA2DS2VASc risk
score is easy to use and provides important information about
prognosis, we can identify patients with a higher risk of
subsequent cardiovascular events with this risk-stratiﬁcation
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